BIO — Bio-Rad Laboratories, Inc.

Bio-Rad Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Net Sales: Approximately $693 million, a 3.9% increase from $668 million in Q4 2024.
• Life Science Segment Sales: $268 million, down 2.6% year-over-year.
• Clinical Diagnostics Segment Sales: $425 million, up 8.4% year-over-year.
• Gross Margin: GAAP gross margin at 49.8%, down from 51.2% in Q4 2024; non-GAAP gross margin at 52.5%, down from 53.9%.
• Operating Loss: Approximately $119 million, compared to operating income of $58 million in Q4 2024, primarily due to $173 million in impairment charges.
• Non-GAAP Net Income: $68 million ($2.51 per diluted share), down from $81 million ($2.90 per diluted share) in Q4 2024.
• Full Year 2025 Net Sales: $2.583 billion, a 0.7% increase from 2024.
• Full Year Non-GAAP Net Income: $271 million ($9.92 per diluted share), down from $291 million ($10.31 per diluted share) in 2024.
• Free Cash Flow: $375 million for 2025, up from $290 million in 2024.

2. Strategic Updates and Business Highlights

• Diagnostics Segment: Returned to growth driven by quality control and blood typing products, with a cautious outlook on reimbursement changes in China.
• Life Science Segment: Strong performance from the QX700 Droplet Digital PCR (ddPCR) platform, with a growing order funnel despite overall market softness.
• Acquisition of Stilla: Expected to be accretive by mid-2026, contributing positively to the ddPCR portfolio.
• Focus on Innovation: Plans for product launches in 2026, including an IVD version of the QX600 and additional ddPCR assays, with an emphasis on incorporating AI into future platforms.

3. Forward Guidance and Outlook

• 2026 Revenue Growth: Expected currency-neutral growth between 0.5% and 1.5%, with Q1 anticipated to decline low single digits year-over-year.
• Life Science Segment Growth: Forecasted to be between 0% and 0.5%, with core Life Science (excluding process chromatography) expected to grow nearly 4%.
• Diagnostics Segment Growth: Projected currency-neutral revenue growth of 1% to 2%.
• Gross Margin: Expected to be between 54% and 54.5% for the full year 2026.
• Operating Margin: Projected between 12% and 12.5% for 2026.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Pressures: Higher-than-anticipated supply chain costs impacted gross margins, with execution-related issues rather than structural problems.
• Decline in Life Science Sales: Driven by a constrained academic research environment and biopharma funding challenges.
• Process Chromatography Segment: Experienced declines due to changes in customer demand and government regulations, with expectations of mid-teens decline in 2026.
• Increased SG&A Expenses: Rising employee-related costs contributed to higher selling, general, and administrative expenses.

5. Notable Q&A Insights

• ddPCR Growth: Strong quarterly growth attributed to the QX700 platform, with a shift towards more instrument sales compared to assays.
• Process Chromatography Outlook: Expected to recover to low single-digit growth by 2027, contingent on customer transitions from clinical to commercial phases.
• Lack of Share Buybacks: No buybacks in Q4 2025, with management indicating a focus on opportunistic investments and potential M&A rather than signaling any negative outlook.
• Market Conditions: Management noted early signs of stabilization in core markets, particularly in NIH funding and diagnostics demand.

Overall, Bio-Rad's Q4 2025 results reflect a mixed performance with strategic initiatives aimed at long-term growth, though challenges remain in certain segments and market conditions.